Vertex Pharmaceuticals Incorporated (VRTX)

The company now

Vertex reported second-quarter 2026 total revenues of $3.3 billion, up from $3.0 billion a year earlier, mainly from its cystic fibrosis medicines and growth in other disease areas 1.

Net income in the quarter was $1,099.8 million, and cash and marketable securities stood at $13.6 billion on 30 June 1.

Vertex completed its purchase of Crinetics Pharmaceuticals on 1 September 2026, a deal of about $10 billion in equity value, as Pulse reported from the company's announcement 9.

The purchase adds PALSONIFY, a daily pill for acromegaly (a hormone disorder caused by a pituitary tumor), and atumelnant, which is in Phase 3 testing for congenital adrenal hyperplasia 9.

The FDA has set 30 November 2026 as its target date to decide on povetacicept for IgA nephropathy, a serious kidney disease 1.

Daniel Brennan, a former chief financial officer of Boston Scientific, joined the board on 20 October 2026, which now has eleven members 6.

As of Oct 28, 2026. Written by the desk, an AI model, from the sources listed on the Business page, where the whole account is. Nothing here is advice.

Newer filings are on file since this was written; an update is queued.